AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Analysts Weigh In on 10x Genomics, Kura Oncology and Insulet: Buy or Hold?
ByAinvest
Wednesday, Aug 13, 2025 7:42 am ET1min read
Analysts have issued new ratings on healthcare companies 10x Genomics (TXG), Kura Oncology (KURA), and Insulet (PODD). Leerink Partners analyst Puneet Souda maintained a Hold rating on TXG with a price target of $16.00, while Jonathan Chang from Leerink Partners reiterated a Buy rating on KURA with a price target of $23.00. Mike Kratky from Leerink Partners also reiterated a Buy rating on Insulet with a price target of $339.00. The analyst consensus on TXG is Moderate Buy with an average price target of $14.90, a 20.7% upside from current levels. KURA has a Strong Buy consensus with a $25.10 average price target, implying a 352.3% upside from current levels. Insulet also has a Strong Buy consensus with a price target consensus of $359.44, a 17.0% upside from current levels.
Analysts have recently issued new ratings and price targets for several healthcare companies, providing investors with valuable insights into their future prospects. Among the companies receiving attention are 10x Genomics (TXG), Kura Oncology (KURA), and Insulet (PODD).10x Genomics (TXG)
Leerink Partners analyst Puneet Souda maintained a Hold rating on TXG with a price target of $16.00 [1]. The overall analyst consensus on TXG is a Moderate Buy, with an average price target of $14.90, representing a 20.7% upside from current levels [1].
Kura Oncology (KURA)
Jonathan Chang from Leerink Partners reiterated a Buy rating on KURA with a price target of $23.00 [1]. KURA has a Strong Buy consensus with an average price target of $25.10, implying a 352.3% upside from current levels [1].
Insulet (PODD)
Mike Kratky from Leerink Partners also reiterated a Buy rating on Insulet with a price target of $339.00 [1]. Insulet also has a Strong Buy consensus with a price target consensus of $359.44, a 17.0% upside from current levels [1].
These new ratings and price targets reflect the analysts' assessments of the companies' growth prospects and strategic positions. Investors should consider these insights alongside their own research and analysis when making investment decisions.
References:
[1] https://www.tipranks.com/stocks/txg/forecast
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet